Ramer Robert, Hinz Burkhard
a Institute of Toxicology and Pharmacology , Rostock University Medical Center , Rostock , Germany.
Expert Opin Ther Targets. 2016 Oct;20(10):1219-35. doi: 10.1080/14728222.2016.1177512. Epub 2016 May 11.
Molecular structures of the endocannabinoid system have gained interest as potential pharmacotherapeutical targets for systemic cancer treatment.
The present review covers the contribution of the endocannabinoid system to cancer progression. Particular focus will be set on the accumulating preclinical data concerning antimetastatic, anti-invasive and anti-angiogenic mechanisms induced by cannabinoids.
The main goal of targeting endocannabinoid structures for systemic anticancer treatment is the comparatively good safety profile of cannabinoid compounds. In addition, antitumorigenic mechanisms of cannabinoids are not restricted to a single molecular cascade but involve multiple effects on various levels of cancer progression such as angiogenesis and metastasis. Particularly the latter effect has gained interest for pharmacological interventions. Thus, drugs aiming at the endocannabinoid system may represent potential 'antimetastatics' for an upgrade of a future armamentarium against cancer diseases.
内源性大麻素系统的分子结构作为全身癌症治疗的潜在药物靶点已引起关注。
本综述涵盖了内源性大麻素系统对癌症进展的作用。将特别关注关于大麻素诱导的抗转移、抗侵袭和抗血管生成机制的临床前数据积累情况。
针对内源性大麻素结构进行全身抗癌治疗的主要目标是大麻素化合物相对良好的安全性。此外，大麻素的抗肿瘤机制不限于单一分子级联反应，而是涉及对癌症进展各个层面（如血管生成和转移）的多种影响。特别是后一种作用已引起药物干预方面的兴趣。因此，针对内源性大麻素系统的药物可能代表未来对抗癌症疾病的武器库升级的潜在“抗转移药物”。
